The historical rank and industry rank for JFL Life Sciences's FCF Margin % or its related term are showing as below:
NSE:JFLLIFE'
s FCF Margin % Range Over the Past 10 Years
Min: -23.16 Med: -4.79 Max: 4.93
Current: -4.79
During the past 7 years, the highest FCF Margin % of JFL Life Sciences was 4.93%. The lowest was -23.16%. And the median was -4.79%.
NSE:JFLLIFE's FCF Margin % is ranked worse than 67.01% of 958
companies
in the Drug Manufacturers industry
Industry Median: 2.445
vs NSE:JFLLIFE: -4.79
JFL Life Sciences FCF Margin % Related Terms
JFL Life Sciences FCF Margin % Historical Data
* Premium members only.
The historical data trend for JFL Life Sciences's FCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, JFL Life Sciences's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
JFL Life Sciences FCF Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, JFL Life Sciences's FCF Margin % distribution charts can be found below:
* The bar in red indicates where JFL Life Sciences's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
JFL Life Sciences (NSE:JFLLIFE) has a FCF Margin % of -4.79% as of Mar. 2025. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on JFL Life Sciences and its competitors. According to the industry distribution chart, JFL Life Sciences ranks #642 out of 958 companies in the Drug Manufacturers industry, placing it in the top 67%.
Is JFL Life Sciences' FCF Margin % too high?
JFL Life Sciences' current FCF Margin % is -4.79%. Based on the distribution chart, JFL Life Sciences ranks #642 out of 958 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, JFL Life Sciences has a GF Score™ of 65/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does JFL Life Sciences' FCF Margin % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, JFL Life Sciences ranks #642 out of 958 companies for FCF Margin %. This places JFL Life Sciences in the lower half of its industry. The industry median FCF Margin % is 2.45. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Drug Manufacturers company?
The median FCF Margin % among Drug Manufacturers companies is 2.45, based on 958 companies in the industry. Companies in the top quartile (top 25%) have a FCF Margin % significantly above this median, while those in the bottom quartile fall well below. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on JFL Life Sciences and its competitors. For the Drug Manufacturers industry, the median FCF Margin % is 2.45 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. JFL Life Sciences's current FCF Margin % is -4.79%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is JFL Life Sciences stock overvalued right now?
Based on GuruFocus' analysis, JFL Life Sciences (NSE:JFLLIFE) is currently considered Significantly Undervalued. The stock's GF Value™ is ₹35.55, compared to a current price of ₹9.05 — trading 74.5% below its estimated fair value. The current FCF Margin % is -4.79%. JFL Life Sciences' overall GF Score™ is 65/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For JFL Life Sciences (NSE:JFLLIFE), the current FCF Margin % is -4.79% as of Mar. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is JFL Life Sciences (NSE:JFLLIFE) Overvalued in 2026?
Based on GuruFocus' analysis, JFL Life Sciences stock appears to be undervalued.
The current stock price of ₹9.05 is trading 74.5% below its estimated GF Value™ of ₹35.55.
GuruFocus considers JFL Life Sciences to be Significantly Undervalued.
Key valuation signals for NSE:JFLLIFE:
FCF Margin %: -4.79%
GF Value™: ₹35.55 vs. price of ₹9.05 (74.5% below fair value)
No single metric tells the full story. See the NSE:JFLLIFE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
JFL Life Sciences Ltd is engaged in the business of manufacturing pharmaceutical products. The company's product portfolio consists of Dry powder injections (B-Lactam), Tablets and Capsules (B-Lactam) solid oral dosage forms, and general tablets and capsules. Its operating segment comprises of manufacturing and selling of pharmaceutical products. Geographically, the company sells its products both in India and outside India.
65GF Score
Get the complete analysis for NSE:JFLLIFE
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:JFLLIFE has been successfully added to your 